Making medicines work better by activating them only where needed
Discovery of solubilizing side chains for in vivo release of diverse drug classes using the Click Activated Protodrugs (CAP) platform
['FUNDING_SBIR_2'] · TAMBO, INC. · NIH-11146646
This project is creating a new way to deliver medicines directly to where they're needed in the body, helping to reduce unwanted side effects for people taking various drugs, including those for cancer.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | TAMBO, INC. (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-11146646 on ClinicalTrials.gov |
What this research studies
Many medicines spread throughout the body, causing side effects in healthy tissues because they aren't specific enough. This project is developing a special system called CAP (Click Activated Protodrugs) that can turn drugs on only at the exact site of a problem, like a tumor. This approach aims to make medicines more effective while greatly reducing harmful side effects. It could also help bring back promising drugs that were previously set aside due to their side effects.
Who could benefit from this research
Good fit: Patients who could benefit from this research are those with conditions requiring potent medications, such as cancer, where current treatments often cause significant side effects.
Not a fit: Patients whose conditions do not require targeted drug delivery or who are not taking medications with significant systemic side effects may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this technology could lead to more effective treatments with fewer side effects for many diseases, potentially allowing patients to tolerate higher, more effective doses of their medication.
How similar studies have performed: While other methods for targeted drug delivery have had limited success due to patient variability, this new CAP platform uses a unique activation method designed to be consistent across different individuals.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- TAMBO, INC. — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: YEE, NATHAN — TAMBO, INC.
- Study coordinator: YEE, NATHAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents